『The Lancet Oncology in conversation with』のカバーアート

The Lancet Oncology in conversation with

The Lancet Oncology in conversation with

著者： The Lancet Group
無料で聴く

Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.© 2026 The Lancet Group 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Iberdomide, daratumumab, and dexamethasone in relapsed or refractory multiple myeloma with Professor Lonial

    Iberdomide, daratumumab, and dexamethasone in relapsed or refractory multiple myeloma with Professor Lonial
    2026/10/26

    Iberdomide, daratumumab, and dexamethasone as a treatment option for patients with relapsed or refractory multiple myeloma.

    Click here the full article:

    S1470-2045(26)00450-X
    続きを読む 一部表示
    7 分
  • Accelerating equitable cancer genomics and precision oncology with Raffaella Casolino and Mark Lawler

    Accelerating equitable cancer genomics and precision oncology with Raffaella Casolino and Mark Lawler
    2026/09/25

    In this special episode, Dr Cheryl Lai, Acting Deputy Editor at The Lancet Oncology, is joined by Dr Raffaella Casolino (University of Glasgow, UK; International Cancer Genome Consortium - Accelerating Research in Genomic Oncology) and Professor Mark Lawler (Queen's University Belfast, UK) to discuss the outcomes and implications of the latest Lancet Oncology Commission on cccelerating equitable cancer genomics and precision oncology in health care and research.

    Explore the Commission and related content:

    https://www.thelancet.com/commissions-do/accelerating-equitable-cancer-genomics

    Look at the infographic:

    https://www.thelancet.com/infographics-do/universal-access-precision-oncology

    Read the full Commission:

    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00302-5
    続きを読む 一部表示
    16 分
  • Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi

    Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi
    2026/08/24

    Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials and clinical practice. The Articles and Review are published in the September 2026 issue of The Lancet Oncology.

    To read the publications discussed, see:

    Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00255-X Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6 Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0
    続きを読む 一部表示
    18 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません